CARLSBAD, Calif., July 28, 2014 /PRNewswire/ -- Isis
Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following
webcast:
What:
|
|
Isis Pharmaceuticals'
Second Quarter 2014 Financial Results and Highlights Conference
Call
|
|
|
|
When:
|
|
Monday, August 4 at
10:30 a.m. ET / 7:30 a.m. PT
|
|
|
|
Where:
|
|
www.isispharm.com
|
|
|
|
How:
|
|
Live on the Internet.
Simply log onto our website listed above.
|
|
|
|
|
|
|
If you are unable to participate during the live event, a replay
of the webcast will be available for a limited time at
www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting
its leadership position in antisense technology to discover and
develop novel drugs for its product pipeline and for its
partners. Isis' broad pipeline consists of 32 drugs to treat
a wide variety of diseases with an emphasis on cardiovascular,
metabolic, severe and rare diseases, including neurological
disorders, and cancer. Isis' partner, Genzyme, is
commercializing Isis' lead product, KYNAMRO®, in
the United States and other
countries for the treatment of patients with homozygous FH.
Isis' patents provide strong and extensive protection for its drugs
and technology. Additional information about Isis is
available at www.isispharm.com.
ISIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding Isis Pharmaceuticals'
financial position and outlook, Isis' business, and the therapeutic
and commercial potential of Isis' technologies and products in
development. Any statement describing Isis' goals,
expectations, financial or other projections, intentions or beliefs
is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. Isis' forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking
statements. Although Isis' forward-looking statements reflect
the good faith judgment of its management, these statements are
based only on facts and factors currently known by Isis. As a
result, you are cautioned not to rely on these forward-looking
statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31,
2013, and its most recent quarterly report on Form 10-Q,
which are on file with the SEC. Copies of these and other
documents are available from the Company.
In this press release, unless the context requires otherwise,
"Isis," "Company," "we," "our," and "us" refers to Isis
Pharmaceuticals and its subsidiaries.
Isis Pharmaceuticals® is a registered trademark of
Isis Pharmaceuticals, Inc. KYNAMRO® is a registered
trademark of Genzyme Corporation.
Logo -
http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
SOURCE Isis Pharmaceuticals, Inc.